JP2017510661A - ツブリシン誘導体 - Google Patents
ツブリシン誘導体 Download PDFInfo
- Publication number
- JP2017510661A JP2017510661A JP2017504616A JP2017504616A JP2017510661A JP 2017510661 A JP2017510661 A JP 2017510661A JP 2017504616 A JP2017504616 A JP 2017504616A JP 2017504616 A JP2017504616 A JP 2017504616A JP 2017510661 A JP2017510661 A JP 2017510661A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- mmol
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1CC*(C)CC1 Chemical compound CC1CC*(C)CC1 0.000 description 7
- PXZQQYSHTZVCGV-OJOFNXSQSA-N CC[C@H](C)[C@@H](C(N(CC)[C@H](C[C@H](c1nc(C(N[C@H](C[C@H]2C(O)=O)Cc(cc3)c2cc3NC([C@H](CCCCN)NC(CCN(C(C=C2)=O)C2=O)=O)=O)=O)c[s]1)OC(C)=O)C(C)C)=O)NC([C@@H]1N(C)CC[C@@H](C)C1)=O Chemical compound CC[C@H](C)[C@@H](C(N(CC)[C@H](C[C@H](c1nc(C(N[C@H](C[C@H]2C(O)=O)Cc(cc3)c2cc3NC([C@H](CCCCN)NC(CCN(C(C=C2)=O)C2=O)=O)=O)=O)c[s]1)OC(C)=O)C(C)C)=O)NC([C@@H]1N(C)CC[C@@H](C)C1)=O PXZQQYSHTZVCGV-OJOFNXSQSA-N 0.000 description 2
- FKDDXVPZPCQHNC-UHFFFAOYSA-N CC(C)(C)OC(N(C)C(CC(O)=O)=C(C)C)=O Chemical compound CC(C)(C)OC(N(C)C(CC(O)=O)=C(C)C)=O FKDDXVPZPCQHNC-UHFFFAOYSA-N 0.000 description 1
- KAZCHYIOVKJUQN-AWEZNQCLSA-N CC(C)(C)OC(N[C@H](CC(C)(C(OC(C)(C)O1)=O)C1=O)Cc(cc1)ccc1[N+]([O-])=O)=O Chemical compound CC(C)(C)OC(N[C@H](CC(C)(C(OC(C)(C)O1)=O)C1=O)Cc(cc1)ccc1[N+]([O-])=O)=O KAZCHYIOVKJUQN-AWEZNQCLSA-N 0.000 description 1
- DZYWNZWYEPQJEL-UHFFFAOYSA-N CC(C)(CC=O)N Chemical compound CC(C)(CC=O)N DZYWNZWYEPQJEL-UHFFFAOYSA-N 0.000 description 1
- NLJHFQQVNJQWTO-QGZVFWFLSA-N CC(C)[C@@H](CC(c1nc(CO[Si+](C)(C)C(C)(C)C)c[s]1)=O)N(C)C(OC(C)(C)C)=O Chemical compound CC(C)[C@@H](CC(c1nc(CO[Si+](C)(C)C(C)(C)C)c[s]1)=O)N(C)C(OC(C)(C)C)=O NLJHFQQVNJQWTO-QGZVFWFLSA-N 0.000 description 1
- AQARNAACOLKILY-AWYHSGSASA-N CC[C@H](C)[C@@H](C(N(CC)[C@H](C[C@H](c1nc(C(NC(C2)(C[C@@H](C(O)=O)c3c4)C2c3ccc4NC([C@H](CCCCN)NC(CCCCCN(C(C=C2)=O)C2=O)=O)=O)=O)c[s]1)OC(C)=O)C(C)C)=O)NC([C@]1(C)N(C)CCCC1)=O Chemical compound CC[C@H](C)[C@@H](C(N(CC)[C@H](C[C@H](c1nc(C(NC(C2)(C[C@@H](C(O)=O)c3c4)C2c3ccc4NC([C@H](CCCCN)NC(CCCCCN(C(C=C2)=O)C2=O)=O)=O)=O)c[s]1)OC(C)=O)C(C)C)=O)NC([C@]1(C)N(C)CCCC1)=O AQARNAACOLKILY-AWYHSGSASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978460P | 2014-04-11 | 2014-04-11 | |
| US61/978,460 | 2014-04-11 | ||
| PCT/US2015/025235 WO2015157594A1 (en) | 2014-04-11 | 2015-04-10 | Tubulysin derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017510661A true JP2017510661A (ja) | 2017-04-13 |
| JP2017510661A5 JP2017510661A5 (enExample) | 2018-05-24 |
Family
ID=54264545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504616A Pending JP2017510661A (ja) | 2014-04-11 | 2015-04-10 | ツブリシン誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9427479B2 (enExample) |
| EP (1) | EP3129362A4 (enExample) |
| JP (1) | JP2017510661A (enExample) |
| KR (1) | KR20160142392A (enExample) |
| CN (1) | CN106458942A (enExample) |
| AR (1) | AR100006A1 (enExample) |
| AU (1) | AU2015243379B2 (enExample) |
| CA (1) | CA2945318A1 (enExample) |
| CL (1) | CL2016002548A1 (enExample) |
| EA (1) | EA032203B1 (enExample) |
| IL (1) | IL247822A0 (enExample) |
| MA (1) | MA39862A (enExample) |
| MX (1) | MX2016013373A (enExample) |
| NZ (1) | NZ725131A (enExample) |
| PH (1) | PH12016501995A1 (enExample) |
| SG (1) | SG11201608203RA (enExample) |
| TW (1) | TW201625662A (enExample) |
| UY (1) | UY36075A (enExample) |
| WO (1) | WO2015157594A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201542594A (zh) | 2014-04-11 | 2015-11-16 | Medimmune Llc | 雙特異性ｈｅｒ２抗體 |
| SG11201608203RA (en) | 2014-04-11 | 2016-10-28 | Medimmune Llc | Tubulysin derivatives |
| SG11201706820RA (en) * | 2015-02-25 | 2017-09-28 | Univ Rice William M | Desacetoxytubulysin h and analogs thereof |
| CA3003468C (en) | 2015-11-10 | 2024-06-18 | Medimmune, Llc | Binding molecules specific for asct2 and uses thereof |
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US10723727B2 (en) * | 2016-02-01 | 2020-07-28 | Pfizer Inc. | Tubulysin analogs and methods for their preparation |
| WO2017180813A1 (en) | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
| US20200023072A1 (en) | 2016-10-11 | 2020-01-23 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| JP7150820B2 (ja) | 2017-08-01 | 2022-10-11 | メディミューン，エルエルシー | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
| US11998584B2 (en) * | 2017-12-31 | 2024-06-04 | Hangzhou Dac Biotech Co., Ltd. | Conjugate of a tubulysin analog with branched linkers |
| CN109456212A (zh) * | 2018-12-03 | 2019-03-12 | 康化（上海）新药研发有限公司 | 一种沙库比曲中间体的合成方法 |
| KR20210106467A (ko) | 2018-12-21 | 2021-08-30 | 리제너론 파마슈티칼스 인코포레이티드 | 튜불리신 및 단백질-튜불리신 접합체 |
| TWI753252B (zh) * | 2019-05-03 | 2022-01-21 | 中國大陸商杭州多禧生物科技有限公司 | 含支鏈連接體的Ｔｕｂｕｌｙｓｉｎ同系物偶聯物 |
| BR112021026142A2 (pt) * | 2019-06-24 | 2022-02-08 | Hangzhou Dac Biotech Co Ltd | Composto conjugado ligado à cadeia lateral da fórmula, célula de tumor, composição farmacêutica, agente quimioterapêutico, e, agentes sinergísticos |
| CA3185601A1 (en) * | 2020-06-24 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| AR123480A1 (es) | 2020-09-11 | 2022-12-07 | Medimmune Ltd | Moléculas de unión terapéuticas |
| JP2024544520A (ja) | 2021-11-10 | 2024-12-03 | アストラゼネカ・アクチエボラーグ | 抗体分子及び複合体 |
| GB202117928D0 (en) | 2021-12-11 | 2022-01-26 | Cancer Research Tech Ltd | Immunotherapy for cancer |
| IL317733A (en) | 2022-06-27 | 2025-02-01 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013501055A (ja) * | 2009-08-03 | 2013-01-10 | メダレックス インコーポレーティッド | 抗増殖性化合物、その抱合体、そのための方法ならびにその使用 |
| WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
| JP2017512765A (ja) * | 2014-04-11 | 2017-05-25 | メディミューン，エルエルシー | 二重特異性ｈｅｒ２抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7064211B2 (en) * | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
| WO2006063135A2 (en) * | 2004-12-09 | 2006-06-15 | Eisai R & D Management Co., Ltd. | Tubulin isotype screnning in cancer therapy using hemiasterlin analogs |
| IT1394860B1 (it) * | 2009-07-22 | 2012-07-20 | Kemotech S R L | Composti farmaceutici |
| MX352738B (es) * | 2011-11-17 | 2017-12-06 | Pfizer | Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos. |
| IN2014CN04961A (enExample) * | 2011-12-05 | 2015-09-18 | Igenica Biotherapeutics Inc | |
| ES2628156T3 (es) * | 2013-02-14 | 2017-08-01 | Bristol-Myers Squibb Company | Compuestos de tubulisina, métodos para su fabricación y su uso |
| SG11201608203RA (en) * | 2014-04-11 | 2016-10-28 | Medimmune Llc | Tubulysin derivatives |
-
2015
- 2015-04-10 SG SG11201608203RA patent/SG11201608203RA/en unknown
- 2015-04-10 MA MA039862A patent/MA39862A/fr unknown
- 2015-04-10 AR ARP150101089A patent/AR100006A1/es unknown
- 2015-04-10 KR KR1020167031176A patent/KR20160142392A/ko not_active Withdrawn
- 2015-04-10 TW TW104111700A patent/TW201625662A/zh unknown
- 2015-04-10 CN CN201580031041.XA patent/CN106458942A/zh active Pending
- 2015-04-10 AU AU2015243379A patent/AU2015243379B2/en not_active Ceased
- 2015-04-10 UY UY0001036075A patent/UY36075A/es not_active Application Discontinuation
- 2015-04-10 NZ NZ725131A patent/NZ725131A/en not_active IP Right Cessation
- 2015-04-10 MX MX2016013373A patent/MX2016013373A/es unknown
- 2015-04-10 US US14/683,196 patent/US9427479B2/en not_active Expired - Fee Related
- 2015-04-10 EP EP15777523.0A patent/EP3129362A4/en not_active Withdrawn
- 2015-04-10 JP JP2017504616A patent/JP2017510661A/ja active Pending
- 2015-04-10 CA CA2945318A patent/CA2945318A1/en not_active Abandoned
- 2015-04-10 WO PCT/US2015/025235 patent/WO2015157594A1/en not_active Ceased
- 2015-04-10 EA EA201691963A patent/EA032203B1/ru not_active IP Right Cessation
-
2016
- 2016-08-08 US US15/230,918 patent/US10159745B2/en not_active Expired - Fee Related
- 2016-09-14 IL IL247822A patent/IL247822A0/en unknown
- 2016-10-06 CL CL2016002548A patent/CL2016002548A1/es unknown
- 2016-10-07 PH PH12016501995A patent/PH12016501995A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013501055A (ja) * | 2009-08-03 | 2013-01-10 | メダレックス インコーポレーティッド | 抗増殖性化合物、その抱合体、そのための方法ならびにその使用 |
| WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
| JP2017512765A (ja) * | 2014-04-11 | 2017-05-25 | メディミューン，エルエルシー | 二重特異性ｈｅｒ２抗体 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160142392A (ko) | 2016-12-12 |
| CN106458942A (zh) | 2017-02-22 |
| TW201625662A (zh) | 2016-07-16 |
| US9427479B2 (en) | 2016-08-30 |
| EA201691963A1 (ru) | 2017-06-30 |
| IL247822A0 (en) | 2016-11-30 |
| EA032203B1 (ru) | 2019-04-30 |
| AR100006A1 (es) | 2016-08-31 |
| US20150291657A1 (en) | 2015-10-15 |
| EP3129362A4 (en) | 2017-08-23 |
| AU2015243379A1 (en) | 2016-11-03 |
| UY36075A (es) | 2015-10-30 |
| MA39862A (fr) | 2017-02-15 |
| SG11201608203RA (en) | 2016-10-28 |
| PH12016501995A1 (en) | 2017-01-09 |
| US20160339114A1 (en) | 2016-11-24 |
| MX2016013373A (es) | 2017-05-02 |
| WO2015157594A1 (en) | 2015-10-15 |
| US10159745B2 (en) | 2018-12-25 |
| AU2015243379B2 (en) | 2018-02-01 |
| NZ725131A (en) | 2018-03-23 |
| CL2016002548A1 (es) | 2017-02-24 |
| CA2945318A1 (en) | 2015-10-15 |
| EP3129362A1 (en) | 2017-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10159745B2 (en) | Tubulysin derivatives | |
| JP7138350B2 (ja) | 共役連結体、該連結体を含有する細胞結合分子－薬物共役体、並びに該共役体及び連結体の使用及び製造方法 | |
| JP6700321B2 (ja) | 細胞結合分子の特異的共役体 | |
| AU2016202632B2 (en) | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | |
| CA2991975C (en) | Novel linkers and their uses in specific conjugation of drugs to a biological molecule | |
| AU2024205004A1 (en) | Anti-EGFR antibody drug conjugates | |
| JP2023530128A (ja) | 細胞結合分子とカンプトテシン類縁体との共役体 | |
| AU2016232839B2 (en) | CD48 antibodies and conjugates thereof | |
| JP2024028815A (ja) | チューブリシン類縁体と細胞結合分子との共役体の製剤 | |
| JP2022172122A (ja) | 細胞結合分子の共役のための架橋連結体 | |
| CA3172516A1 (en) | Degrader-antibody conjugates and methods of using same | |
| KR20210106467A (ko) | 튜불리신 및 단백질-튜불리신 접합체 | |
| EP4480499A1 (en) | Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof | |
| TW202114740A (zh) | 一種細胞結合分子-tubulysin衍生物偶聯物及其製備方法 | |
| JP2020063254A (ja) | 細胞結合分子の特異的共役体 | |
| JP2020524669A (ja) | 抗ｇｌｏｂｏ ｈ抗体を含有する抗体−薬物コンジュゲートおよびその使用 | |
| US20240342302A1 (en) | Degrader-antibody conjugates and methods of using same | |
| JP2023159139A (ja) | 新規な連結体及び生体分子と薬物との特異的共役におけるその使用 | |
| EP4623937A1 (en) | Anti-tumor compound and use thereof | |
| WO2025105486A1 (ja) | 抗体－光感受性物質コンジュゲート |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180409 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180409 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190226 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190527 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190725 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20191029 |